John Radcliffe Hospital

Running trials

• Recruiting

  Mechanisms of Repeated Real-time Biofeedback With 7-Tesla MRI in Depression

  NCT07694076· University of Oxford· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

  NCT06987539· Phase 2· Amgen· Source

• Recruiting

  Comparative Evaluation of Sustained meChanical AsPiration Thrombectomy and no Thrombus Modification for Pre-stent Thrombus bUrden Reduction in Patients With Acute Myocardial Infarction Study: the CAPTURE AMI Study

  NCT07687576· Phase 2/3· Oxford University Hospitals NHS Trust· Source

• Recruiting

  DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Phase 2/3· Cancer Research UK· Source

• Recruiting

  Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration

  NCT07523620· Abbott Medical Devices· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)

  NCT07286578· Fundación EPIC· Source

• Recruiting

  DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

  NCT05770544· Phase 2/3· Cancer Research UK· Source

• Enrolling by invitation

  Optical Coherence Tomography in Acute Vessel Evaluation

  NCT07422688· Aarhus University Hospital Skejby· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Neuropsychiatric Outcomes and Disrupted Sleep Following Acquired Brain Injury

  NCT07215195· University of Oxford· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Genentech, Inc.· Source

• Not yet recruiting

  Improving Diagnosis and Treatment for Patients With Rectal Cancer

  NCT07054047· Imperial College London· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

  NCT06953583· Phase 3· Biogen· Source

• Recruiting

  PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]

  NCT06923111· Nova Laboratories Limited· Source

• Recruiting

  Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis

  NCT06940531· Alexander Horsley· Source

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Joseph Broderick, MD· Source

• Recruiting

  Ambroxol to Slow Progression in Parkinson Disease

  NCT05778617· Phase 3· University College, London· Source

• Recruiting

  A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

  NCT07334301· Phase 1/2· University of Birmingham· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· AbbVie· Source

• Recruiting

  Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery

  NCT04103372· Imperial College London· Source

• Recruiting

  A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

  NCT06565195· Phase 1· Prevail Therapeutics· Source

• Recruiting

  Efficacy of Pain Intervention With Deep Brain Stimulation Neuromodulation

  NCT06387914· University of Oxford· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Enrolling by invitation

  Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - SUMMIT (Part 2)

  NCT06682455· University of Southampton· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Frontosubthalamic Networks in Parkinson's Disease.

  NCT06485986· University of Oxford· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05923073· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Capillary OGTT Study

  NCT06815081· University of Oxford· Source

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Orchestra BioMed, Inc· Source

• Recruiting

  DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

  NCT05770037· Phase 2/3· Cancer Research UK· Source

• Active, not recruiting

  A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

  NCT06128564· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

  NCT05770102· Phase 2/3· Cancer Research UK· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

  NCT05817942· Alfasigma S.p.A.· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

  NCT05568069· University Hospital Southampton NHS Foundation Trust· Source

• Recruiting

  DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

  NCT05786716· Phase 2/3· Cancer Research UK· Source

• Recruiting

  DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

  NCT05722886· Phase 2/3· Cancer Research UK· Source

• Recruiting

  A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

  NCT05822908· Phase 1/2· Vico Therapeutics B. V.· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction

  NCT05878912· University of Oxford· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

  NCT04165486· Phase 1· Ionis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

  NCT05337553· Phase 3· Biohaven Pharmaceuticals, Inc.· Source

Showing 50 of 69.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• Colorectal cancer5 recruiting
• Coronary artery disease4 recruiting
• Crohn's disease4 recruiting
• Epilepsy3 recruiting
• Liver and biliary tract cancer3 recruiting
• Melanoma3 recruiting
• Ovarian cancer3 recruiting
• Parkinson disease3 recruiting
• Stroke3 recruiting
• Heart failure2 recruiting
• Lung cancer2 recruiting
• Neuroblastoma2 recruiting
• Type 1 diabetes2 recruiting
• Ulcerative colitis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• High blood pressure1 recruiting
• Huntington's disease1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Macular degeneration1 recruiting
• Multiple myeloma1 recruiting
• Multiple system atrophy1 recruiting
• Myasthenia gravis1 recruiting
• Obesity1 recruiting
• Pancreatic cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Prostate cancer1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoma1 recruiting
• Sickle cell disease1 recruiting
• Thyroid cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Hoffmann-La Roche· Source

• Terminated

  To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

  NCT06488911· Phase 3· Intercept Pharmaceuticals· Source

• Withdrawn

  Shape vs Substrate in AF

  NCT05993104· Oxford University Hospitals NHS Trust· Source

• Completed

  A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction

  NCT05887271· Phase 2/3· University of Leicester· Source

• Completed

  Early Discharge After Mitral and Tricuspid Edge-to-edge Repair: an Assessment of Feasibility and Safety

  NCT06343363· Oxford University Hospitals NHS Trust· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source

• Completed

  A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

  NCT05115110· Phase 2/3· Hoffmann-La Roche· Source

• Completed

  Simulation Training in Emergency Department Imaging 2

  NCT05427838· Oxford University Hospitals NHS Trust· Source

• Completed

  MotIoN aDaptive Deep Brain Stimulation for MSA

  NCT05197816· University of Oxford· Source

• Completed

  Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

  NCT04931771· ECRI bv· Source

• Terminated

  Comparison of the Performance of ICM and CIED in Detecting AF

  NCT04940156· Oxford University Hospitals NHS Trust· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  SAPIEN 3 Ultra EU PMS

  NCT04860752· Edwards Lifesciences· Source

• Completed

  Verapamil SR in Adults With Type 1 Diabetes

  NCT04545151· Phase 2· Medical University of Graz· Source

• Completed

  Cartesia eXTend 3D Study

  NCT04577651· Boston Scientific Corporation· Source

• Terminated

  HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04566445· Phase 2· Gyroscope Therapeutics Limited· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

  NCT04166773· Phase 2· Eli Lilly and Company· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Gyroscope Therapeutics Limited· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Hoffmann-La Roche· Source

• Completed

  Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

  NCT03584165· Phase 3· NightstaRx Ltd, a Biogen Company· Source

• Completed

  Multiple Sclerosis-Simvastatin Trial 2

  NCT03387670· Phase 3· University College, London· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· LivaNova· Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Boston Scientific Corporation· Source

• Completed

  Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT02500381· Phase 3· Sarepta Therapeutics, Inc.· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· University of Calgary· Source

• Recruiting

  Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

  NCT02071134· Boston Scientific Corporation· Source

• Completed

  Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

  NCT01868269· Phase 3· Institut Curie· Source

• Completed

  Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

  NCT01467427· Phase 3· Novo Nordisk A/S· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Neuromyelitis optica (NMOSD)12 works · 0 trials
• Hydrocephalus8 works · 0 trials
• Primary biliary cholangitis4 works · 2 trials
• Retinitis pigmentosa3 works · 1 trial